Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy

NCT00075842 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: The herb Valeriana officinalis (valerian) may promote sleep. It is not yet known whether valerian is effective in improving sleep in patients who are receiving adjuvant therapy for cancer. PURPOSE: This randomized phase III trial is studying how well valerian improves the quality of sleep in patients who are receiving adjuvant therapy (radiation therapy, chemotherapy, or hormone therapy) for cancer.

Interventions

  • OTHER placebo
  • DIETARY_SUPPLEMENT Valeriana officinalis extract

Study Locations (20)

Colorado

  • Aurora Presbyterian Hospital — Aurora
  • Boulder Community Hospital — Boulder
  • Penrose Cancer Center at Penrose Hospital — Colorado Springs
  • Porter Adventist Hospital — Denver
  • Presbyterian - St. Luke's Medical Center — Denver
  • St. Joseph Hospital — Denver
  • Rose Medical Center — Denver
  • CCOP - Colorado Cancer Research Program — Denver
  • Swedish Medical Center — Englewood
  • Sky Ridge Medical Center — Lone Tree
  • Hope Cancer Care Center at Longmont United Hospital — Longmont
  • St. Mary - Corwin Regional Medical Center — Pueblo
  • North Suburban Medical Center — Thornton

Iowa

  • Mercy Cancer Center at Mercy Medical Center - North Iowa — Mason City
  • Siouxland Hematology-Oncology Associates, LLP — Sioux City
  • St. Luke's Regional Medical Center — Sioux City

Minnesota

  • Fairview Ridges Hospital — Burnsville
  • Mercy and Unity Cancer Center at Mercy Hospital — Coon Rapids
  • Fairview Southdale Hospital — Edina

Kansas

  • CCOP - Wichita — Wichita

Trial Details

FieldValue
Enrollment Target 227 participants
Start Date 2003-08
Est. Completion 2010-01
Phase Phase 3

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00075842

The ClinicalTrials.gov registry entry for NCT00075842 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00075842 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Colorado, Iowa, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00075842 about?

NCT00075842 is a clinical study titled "(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy". RATIONALE: The herb Valeriana officinalis (valerian) may promote sleep. It is not yet known whether valerian is effective in improving sleep in patients who are receiving adjuvant therapy for cancer. PURPOSE: This randomized phase III trial is studying how well valerian improves the quality of slee...

What is the current status of trial NCT00075842?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 227 participants. The study started on 2003-08. Estimated completion is 2010-01.

What conditions does trial NCT00075842 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Fatigue, Sleep Disorders. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00075842?

The interventions under investigation include: placebo (OTHER), Valeriana officinalis extract (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00075842?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00075842 being conducted?

This trial has 20 study locations across Colorado, Iowa, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial